Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026073 | 0.94 | SIGMAR1 (0.51) | SIGMAR1NPSR1EGFRL3MBTL1CNR1 | |
| SCHEMBL13483883 | 0.90 | SIGMAR1 (0.48) | SIGMAR1NPSR1EGFRHDAC3HDAC2 | |
| SCHEMBL21026147 | 0.90 | MCHR1 (0.47) | SIGMAR1MCHR1ALDH1A1 | |
| SCHEMBL21025978 | 0.84 | SIGMAR1 (0.51) | SIGMAR1NPSR1EGFRHDAC3HDAC2 | |
| SCHEMBL18731897 | 0.83 | KMO (0.56) | EGFRHDAC3HDAC2MCHR1ALDH1A1 | |
| SCHEMBL21025999 | 0.83 | EGFR (0.42) | SIGMAR1NPSR1EGFRHDAC3HDAC2 | |
| SCHEMBL17673722 | 0.80 | EGFR (0.56) | EGFRHDAC3HDAC2MCHR1HDAC1 | |
| SCHEMBL521061 | 0.80 | HDAC3 (0.47) | EGFRHDAC3HDAC2MCHR1CNR1 | |
| SCHEMBL21026002 | 0.79 | MCHR1 (0.53) | MCHR1 | |
| SCHEMBL14093244 | 0.78 | HDAC3 (0.46) | HDAC3HDAC2MCHR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | SIGMAR1 3139/4885NPSR1 1404/4885EGFR 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.